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Abstract
The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a
result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission
tomography (PET), being used in490% of scans, and is useful for diagnosis, staging and detection of residual/
recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The develop-
ment of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will
complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to
consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver
clinical benefit in cancer, using breast cancer as a paradigm.
Keywords: Assessing therapy response; breast cancer; diagnosis; identification of recurrence; pharmacological biomarker; positron
emission tomography; predictive biomarker; staging; surrogate response biomarker; tumour subtyping.
Introduction
The use of molecular/genetic markers to identify sub-
types of specific cancers and the development of novel
targeted drugs represent significant advances that will
affect cancer, with the potential to realise a more strati-
fied approach to cancer care. These advances, combined
with simultaneous developments in imaging, will create
new opportunities for positron emission tomography
(PET) to help improve clinical outcomes in cancer.
Breast cancer was chosen as an exemplar, as PET
currently has a limited role in this indication, but this
could expand significantly as a result of ongoing
tumour characterisation at the molecular level, and
the range of targeted therapies being developed for this
disease. This article considers these new opportunities
for PET.
Effect on patient care and
opportunities for PET
Breast cancer remains the second most common cause of
cancer-related death in British women, with more than
12,000 deaths per year[1] despite substantial improve-
ments in management, including the introduction of
mammography screening, contrast-enhanced magnetic
resonance imaging (MRI), local treatment of early
stage disease and new therapies. PET is not widely
used in breast cancer management at present but this
may change with two technical advances that increase
instrument sensitivity: (1) PET scanners with time-of-
flight capability can identify the location of annihilation
events more accurately than conventional machines;
this improves the spatial resolution of the recon-
structed image by reducing background noise levels[2];
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(2) dedicated breast PET/CT scanners with higher spa-
tial resolution and photon sensitivity than whole-body
scanners are currently being characterised[3].
The developments of tumour subtyping and the avail-
ability of a broader range of treatments[4] are likely to
lead to changes in how patients with breast cancer are
managed clinically, as summarised in Fig. 1. Compared
with traditional care pathways, the identification of
cancer subtypes represents a new step. Next, based on
tumour subtype, either alone or in combination with con-
ventional staging information, specific treatments or
combinations of treatments may be selected from
amongst an increasing number of available targeted
therapies. Furthermore, PET offers opportunities to mea-
sure functional aspects of the tumour microenvironment,
predict response to treatment and assess response early
rather than at the traditional time point on completion of
therapy[5,6]. Earlier response assessment could poten-
tially allow ineffective treatments to be changed, reducing
the likelihood of treatment-associated morbidity. This
approach creates new opportunities for PET at several
points in the care pathway.
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Figure 1 Emerging paradigm for cancer treatment. (A) The traditional cancer care pathway, in which imaging is used
for diagnosis, staging and assessment of tumour response. The stage determines the treatment option: surgery for
localised disease, radiotherapy for locoregional disease and chemotherapy for systemic disease. (B) The development of
tumour subtyping and the availability of a wider range of targeted treatments is changing this paradigm such that
treatment selection can be made on the basis of combined tumour subtype and staging. There is also an increased
number of treatment options (A, B, C,. . .,N) which often comprise a combination of modalities and chemotherapeutic
agents tailored to the patients subtype and stage. PET can be used as a functional baseline tool to predict response and
can be used to assess early response after only one or two cycles of treatment.
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Diagnosis
The poor sensitivity and high expense of PET means
it is not a cost-effective primary screening method.
Fluorodeoxyglucose (FDG) has low sensitivity for detec-
tion of small (51 cm) and low-grade tumours, because
breast tumours tend to have a low rate of glucose metab-
olism, resulting in many false-negative results. The uptake
of FDG is higher in triple negative subtypes (i.e. basal-
like) breast cancers than in ERþ/PRþ/HER2
tumours[7], but this finding is unlikely to affect the use
of FDG-PET for staging because the subtype is not
known at the time of diagnosis.
Staging
FDG-PET is currently not used in early stage breast
cancer, but there is some evidence that it could be
useful in more advanced cancers, specifically node-posi-
tive tumours greater than 2 cm in diameter (T2, N13),
tumours greater than 5 cm (T3) and tumours with evi-
dence of invasion of skin or chest wall (T4)[8]. MRI is
advocated to assess the local extent of disease in the
breast and although there a number of advocates for
this to reduce reoperation rates and local recurrence, a
recent large multicentre trial has suggested that MRI is
not useful[9]. FDG-PET is useful for detecting locoregio-
nal disease[10], but does not eliminate the need for sen-
tinel lymph node biopsy (SLNB) or axillary lymph node
dissection (ALND)[11,12]; Metastasis is highly likely in
axillary nodes with high FDG uptake, so patients require
axillary dissection, whereas an axillary biopsy is still
required with no uptake of FDG in the axilla. However,
FDG-PET may be a useful test to select patients for
SLNB or ALND[11]. Neither mammography nor ultra-
sound with guided biopsy have proved successful
in robustly identifying patients with nodal disease.
Contrast-enhanced MRI has been promising[13], and
the use of ultrasmall iron oxide particles has been inves-
tigated with encouraging results, but neither technique is
used in day to day practice.
In addition, the finding of greater FDG uptake in triple
negative cancers[7] raises the possibility that FDG-PET
may be useful in staging specific tumour subtypes.
However, this targeted application of FDG-PET is yet
to be subject to clinical trials.
New PET tracers may be able to improve on FDG by
increasing the sensitivity, specificity or accuracy of stag-
ing late-stage tumours. FDG-PET has demonstrated some
utility in detecting metastases. A range of novel PET
tracers could generate data on different metastases to
complement FDG-PET (e.g. [18F]fluoride is often supe-
rior at detecting bone metastases than FDG[14]). Other
new probes could help to elucidate the biochemical
nature of the metastasis (e.g. [18F]misonidazole which
detects hypoxia) and whether this is homogeneous or
heterogeneous. Moreover, some novel PET tracers (e.g.
radiotracers that bind the ER or HER2) could be useful
predictive biomarkers for breast cancer tumours, and aid
identification of heterogeneous tumours that may not be
fully responsive to single therapy treatment.
Tumour subtyping
There is ever increasing evidence that breast cancer is not
one homogeneous disease, but composed of several
related, but distinct, subtypes. Molecular profiling of
breast cancer has identified at least five different subtypes
of this disease, each of which displays a unique gene
expression pattern[15], distinct prognosis[16], and differ-
ent sensitivity to a range of anti-cancer drugs[16].
Luminal cancers are the most common subtype of
breast cancer (60%); they characteristically express the
oestrogen receptor (ER) and progesterone receptors
(PR) and typically contain wild-type p53 protein.
Luminal breast cancers are further subdivided into A
and B subtypes; luminal A generally has a higher expres-
sion of ER-related proteins than B and lower expression
of proteins that promote proliferation. Luminal breast
cancers have a good overall prognosis, although luminal
B has a somewhat poorer outcome than A. Luminal A
breast cancers usually respond well to hormonal therapy,
whereas conventional chemotherapy is often ineffective.
In contrast, both endocrine therapy and chemotherapy
are often beneficial in luminal B breast cancers.
The HER2 subtype refers to breast cancer tumours
that overexpress the HER2 receptor, irrespective of ER
and PR expression. HER2 breast cancers comprise
approximately 20% of breast tumours, generally contain
a high proportion (4080%) of mutated p53 protein and
have a poor prognosis. HER2 breast cancer tumours are
sensitive to anthracycline and taxane-based chemother-
apy, but treatment of these tumours has been dramati-
cally improved by the introduction of HER2-targeted
therapies such as trastuzumab.
The basal-like subtype encompasses approximately
10% of breast cancers, and the majority of these patients
are described as having triple negative receptor status,
because they do not contain significant levels of ER,
PR or HER2. Basal-like breast cancers have a high pro-
portion of mutated p53 protein, low levels of BRCA1, are
more likely to overexpress poly(ADP-ribose) polymerase
(PARP) and generally have a poor prognosis. Many, but
not all, cases of this breast cancer subtype respond to
chemotherapy treatments such as anthracyclins or tax-
anes, suggesting that its poor prognosis is probably due
to the intrinsic biology of the subtype.
Normal breast-like cancer has the lowest occurrence
(approximately 5%) of all of the breast cancer subtypes
and is characterised by low expression levels of ER and
luminal epithelial genes, high expression of basal epithe-
lial genes and usually has a reasonably good clinical prog-
nosis. Not all authorities recognise it as a separate and
well-defined subset.
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The understanding that breast cancer is composed of
several subtypes with different molecular and clinical
properties is a significant advance, because this allows
the possibility of selecting anti-cancer treatment(s) that
are likely to have a higher probability of success in each
subtype, as well as developing specific therapies to treat
each breast cancer subtype. Some of the promising new
therapies currently being developed are described below
and shown in Fig. 2.
Angiogenesis inhibitors
Tumour growth and dissemination depends on the devel-
opment of a neovasculature and vascular endothelial
growth factor (VEGF) is a key stimulator of angiogen-
esis. The VEGF receptor is overexpressed in some breast
cancers, and pathways related to angiogenesis are
overrepresented in the basal subtype[17], suggesting a
potential therapeutic role for angiogenesis inhibitors.
Bevacizumab inhibits growth in several different solid
tumours by binding to and sequestering VEGF, and
having demonstrated activity in advanced breast cancer,
is now being tested in the setting of early, curable breast
cancer[18]. Other agents that modulate VEGF signalling
(e.g. sorafenib which inhibits the VEGF receptor, B-Raf
and c-kit) are also being considered for breast cancer.
Epidermal growth factor receptor inhibitors
A number of new inhibitors that target members of the
epidermal growth factor receptor (EGFR) family are in
clinical development. The most promising of these are
lapatinib, a dual EGFR1 and 2 (HER2) inhibitor and
pertuzumab, a monoclonal antibody that prevents the
dimerisation of HER2[19]. EGFR1 expression is observed
only in basal-like and HER2 positive breast cancer[20],
making these subtypes prospective targets for lapatinib
therapy. Lapatinib has recently been approved for treat-
ment of HER2þ breast cancers, but has not been partic-
ularly effective in basal-like breast cancers, suggesting
that this subtype is not dependent on EGF signalling.
Pertuzumab will only be effective in the HER2 subtype,
and is likely to be used as an alternative to herceptin, or
more probably in combination with that drug.
Insulin-like growth factor inhibitors
Insulin-like growth factor 1 receptor (IGF1R) is asso-
ciated with the growth, invasion and metastasis of
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Figure 2 Promising new anti-cancer agents in breast cancer. The figure summarises some of the most promising agents
that are being developed for breast cancer, and how inhibition of each target may affect some of the key signalling
pathways and biological processes in an individual tumour cell. # represents activation, ? represents inhibition.
Abbreviations: EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IGF1R, insulin-
like growth factor 1 receptor; MEK, MAPK/extracellular signal-regulated kinase kinase; mTOR, mammalian target of
rapamycin; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; VEGF(R), vascular endothelial growth factor
(receptor).
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breast cancer[21]. At present, the relative importance of
the IGF1R signalling pathway in each breast cancer sub-
type is not clear. The IGF1R pathway has been impli-
cated in resistance to cytotoxic agents and targeted
therapies such as those that inhibit the ER, HER2 and
the EGFR[22]. Several IGF1R inhibitors are in clinical
development (e.g. monoclonal antibodies CP-751,871,
IMC-A12, AMG-479 and MK-0646) and it has been sug-
gested that these agents may be particularly effective at
reversing or treating resistance to chemotherapeutic or
targeted breast cancer treatment[22].
Src inhibitors
Src plays an important role in the cross-talk between
proliferative signalling pathways downstream of receptors
such as the ER, IGF1R and the EGFR family, and src
kinase activity is enhanced in breast cancer patients,
making it a potential target for targeted therapeutics.
Several promising anti-cancer agents are being developed
for this target, including dasatinib, bosutinib and
AZD0530[23]. Preclinical data suggest that Src inhi-
bitors may be effective as a single agent in basal-like
tumours[24], or a part of a combination therapy with
other targeted agents[23] in multiple breast cancer
subtypes.
Inhibitors of the PI3K/PKB/
mTOR pathway
Phosphatidylinositol 3-kinase (PI3K), protein kinase B
(PKB) and mammalian target of rapamycin (mTOR)
are inter-connected signalling proteins that are involved
in cell survival. PI3K/PKB activates various anti-apopto-
tic pathways, whereas mTOR (a downstream effector of
PI3K/PKB) regulates cell cycle transition. These proteins
play a key signalling role downstream of many cell sur-
face receptors such as HER2 and the EGFR, and other
signalling systems that drive proliferation including ER.
They have also been implicated in resistance to tamoxifen
and oestrogen deprivation[25]. Development of PI3K/
PKB inhibitors is still at an early stage, whereas several
mTOR inhibitors (e.g. the rapamycin derivatives temsir-
olimus and everolimus) are further advanced[18]. It
has been suggested that combining mTOR inhibitors
with agents that modulate oestrogen signalling or
HER2/EGFR signalling pathways may be an effective
strategy[18].
PARP inhibitors
Activation of PARP-1 is part of a key cellular response to
single-strand DNA breaks, and stimulates DNA repair
through base excision repair. PARP-1 also binds to
double-strand DNA breaks preventing accidental recom-
bination of homologous DNA. PARP inhibitors
(e.g. AZD2281[18]) could improve several breast cancer
chemotherapy regimes by enhancing the activity of
DNA damaging agents and helping to overcome DNA
repair-mediated resistance. PARP inhibitors could be par-
ticularly effective in basal-like tumours, which tend to
have low levels of BRCA1[20]; BRCA1 dysfunction can
sensitise cells to inhibition of PARP activity[26].
Identification of tumour subtypes is currently per-
formed using histological techniques. Several molecular
tests that assess the gene expression pattern are now
available[27]. These are cheaper than PET and have the
potential to produce a much bigger dataset resulting in
better prognostic profiling. Although identification of
molecular imaging correlates for specific tumour sub-
types is conceivable, it is unlikely that PET will be used
routinely to identify breast cancer subtypes. However,
PET may provide complementary biological information
about a specific tumour that could further advance the
subtyping process by providing additional prognostic
information. Efficient management of breast cancer
requires good prognostic tests to allow the appropriate
treatment (e.g. endocrine therapy or chemotherapy) to
be administered to the patients who are most likely to
benefit from each therapy. This use of PET has some
distinctive properties that could overcome problems
associated with biopsies such as: absence of biopsies,
impracticality of taking biopsies, sampling errors and
when there are differences of target expression between
the primary tumour and metastasis. Moreover, in cases
where a metastasis is hard to biopsy, PET may help to
confirm that the metastasis has the same subtype
characteristics.
Relevant biological processes for which PET probes
are available include hypoxia, multidrug resistance, angio-
genesis and receptor expression. Radiotracers that
detect hypoxia (e.g. [18F]MISO and [64Cu]diacetyl-bis
(N4-methylthiosemicarbazone)) may produce a specia-
lised role for PET, because hypoxic tumours tend to be
more aggressive and less likely to respond to a range of
treatments[28]. Indeed, recent data have suggested that
the basal-like subtype contains higher levels of proteins
associated with hypoxia than other subtypes[29], suggest-
ing that this could be associated with the poor prognosis
in this subtype. Although [18F]MISO has been tested in
breast cancer patients[30], a hypoxia PET study has not
yet been used to stratify breast cancer patients; early
identification of hypoxic tumours could improve clinical
outcome by promoting the appropriate use of hypoxia-
targeting therapies. Similarly, the availability of PET
radiotracers that can detect multidrug resistance could
permit early identification of tumours unlikely to respond
to multiple chemotherapeutic agents. In a pilot study,
4-[18F]fluoro-paclitaxel was tested in breast cancer[31],
but no subsequent studies have been carried out.
Pathways related to angiogenesis are overrepresented
in the basal subtype[17], suggesting that it may be possible
to identify this subtype using an angiogenesis tracer.
[18F]Galacto-RGD, which binds to a key integrin
involved in angiogenesis, has been studied in breast
cancer[32], but has not yet been used to identify tumour
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subtypes. The availability of novel radiotracers that bind
to receptors (e.g. oestradiol derivatives or ligands that
bind HER2) will give PET the potential to further stratify
the patient population. A radiolabelled oestradiol deriva-
tive has been used successfully in breast cancer[33.34], but
this tracer has not yet been used to link the relative level
of the radiotracer to tumour subtype.
Tumour stem cells (TSC) are often associated with a
poor prognosis, because they seem to be particularly
resistant to chemotherapy and radiotherapy, and adept
at stimulating angiogenesis. By detecting TSCs and iden-
tifying TSC subtypes, PET could be used to categorize
patients who are more likely to be resistant to chemother-
apy and radiotherapy. Suitable PET ligands could be
developed to fulfil these roles as our understanding of
TSC progresses.
Combined assessment of multiple imaging probes is
likely to lead to more precise assessment of tumour biol-
ogy and more accurate prognosis. For example, com-
bined imaging of angiogenesis and metabolism with
[15O]water and FDG has been shown to predict likely
response of advanced breast cancer to neoadjuvant che-
motherapy[35]. Similarly, a preliminary PET-CT study
that used the CT component to assess angiogenesis by
perfusion imaging, combined with FDG-PET for metab-
olism, observed that the relationship between tumour
metabolism and blood flow may be related to tumour
grade[36].
PET and the development of
new therapies
Efficient development, testing and approval of most new
anti-cancer agents will require an innovative approach
and a new set of skills and tools. Traditionally, cytotoxic
drugs have been optimised by identifying the maximum
tolerated dose of the agent, and screening for efficacy
based on tumour shrinkage. Subsequent clinical trials
seek to identify an effective dose that is associated with
an acceptable level of toxicity. Many of the targeted
agents that are now being developed will probably be
efficacious only in a specific subset of patients, and it
is likely that neither toxicity nor significant tumour
shrinkage will be suitable surrogate end points for detect-
ing activity or selecting the appropriate dose. New tracers
that are currently being developed for PET will assist the
development of targeted anti-cancer agents by acting as
predictive, pharmacological and surrogate response bio-
markers, and extend the utility of this imaging technique
making it well placed to facilitate development of new
drugs.
Predictive biomarkers to identify
patient subpopulations
For targeted anti-cancer agents it is crucial that the
tumour cell population being treated expresses the
target of interest and that the tumour shows dependency
on the target (e.g. trastuzumab in HER2 subtype).
Several inexpensive non-imaging techniques can readily
identify the presence of the target in tumours, assuming
that an appropriate biopsy is available. Novel predictive
biomarkers (e.g. radiolabelled oestradiol derivatives[33]
or PARP-1 binding ligand[37] will be required for PET
to fulfil these potential roles in studying the level and
distribution of important targets.
Pharmacological biomarkers
PET has a number of attractive attributes that are likely
to make it a very useful technique for studying new
agents in vivo to support their development[38]. PET
can examine sensitive molecular processes without per-
turbing them, so as novel radiotracers become available
to study proliferation, apoptosis, angiogenesis and
hypoxia, it will be possible to perform proof of concept
pharmacodynamic studies to ascertain whether an agent
is modulating tumour biology. For example, therapeutics
that primarily inhibit cell growth (e.g. EGFR inhibitors)
rather than promoting cell death could be studied with
the tracer [18F]fluorothymidine (FLT), a surrogate
marker of cell proliferation. Similarly, [18F]galacto-
RGD, a surrogate marker of angiogenesis, may be
useful for studying therapeutics that inhibit angiogenesis
(e.g. bevacizumab). Moreover, the broad applicability of
PET will permit detailed proof of mechanism studies,
using radiolabelled versions of new breast cancer
agents. This will be particularly useful for studying bind-
ing of agents to receptors, allowing values to be derived
for receptor number, binding affinity and binding poten-
tial. This will provide confirmation that an agent interacts
with its target (e.g. oestradiol derivatives binding to
ER[33]), and by studying the level of receptor occupation
it will be possible to optimise the dose and schedule of
the therapeutic.
The generation of intricate pharmacokinetic data
makes a considerable contribution to the drug develop-
ment process, so pharmacokinetic PET studies are likely
to become increasingly important to pharmaceutical com-
panies. By applying mathematical modelling to PET data,
pharmacokinetic information can be calculated on the
kinetics, dosimetry and distribution of radiolabelled
drugs in diseased and normal tissue, as well as plasma
clearance rates[39]. This information can contribute to
go/no go decisions on new therapeutics, by informing
researchers if the agent goes to the target tissue or
normal tissue, and whether it is retained in the body
for long enough to have an effect on its biological target.
Another important parameter that can be generated
from PET studies is the standardised uptake value
(SUV). The SUV gives a measure of tracer uptake in
the region of interest relative to a uniform distribution
over the body. Use of SUVs eliminates the subjective
nature of visual analysis to obtain a more objective assess-
ment of treatment response[40]. SUVs can produce the
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added advantage of allowing responses to be identified
earlier in the treatment cycle[41]. However, to obtain
meaningful SUVs it is important that a standardised pro-
tocol is used throughout the study, and that the same
scanner is used for protocols that involve longitudinal
scans[40].
Surrogate response biomarkers to
demonstrate drug efficacy
Since most targeted agents are not expected to produce
significant tumour shrinkage, surrogate end points will be
required to demonstrate clinical efficacy. Quantitative
PET data are likely to play a key role in assessing
response to therapy. In principle, most radiotracers that
generate SUV values could be used as surrogate response
biomarkers, including tracers that measure glucose
metabolism, cell proliferation and apoptosis, as well as
agents that bind to receptors such as HER2 and the
ER. To date, decreases in the SUV of glucose meta-
bolism[4244], cell proliferation[45,46] and the oestrogen
receptor[33,34] have been used to identify effective thera-
pies in breast cancer patients. PET surrogate response
biomarkers have been used to demonstrate the efficacy
of diverse chemotherapy regimes[42,43,45,46], as well as
different strategies to modulate oestrogen signalling[33,34]
in breast cancer.
Many anti-cancer agents can directly or indirectly
affect the pathways, glucose transporters or metabolic
enzymes controlling glycolysis[47], resulting in decreased
FDG uptake into tumours. Therefore changes in the
FDG uptake rate could provide very early evidence of
drug activity for many of the agents being developed,
such as inhibitors of angiogenesis, the IGF1R and
PI3K/PKB/mTOR, where surrogate response biomarkers
are not available to study the particular pathway under
investigation. FDG-PET has several limitations, although
some of these can be overcome by data from an accom-
panying CT scan. The PET image has limited spatial
resolution and cannot accurately identify anatomical fea-
tures. It can take more than 20min for a full body scan,
which can result in breathing movement artefacts. Some
tumours and metastases are not detected as a result of
poor tracer uptake. Some non-cancerous cells exhibit
increased FDG uptake (e.g. tissues with high proportion
of inflammatory cells), which can make it hard to distin-
guish between cancerous and non-cancerous tissue. It will
be important to establish the limitations associated with
each non-FDG radiotracer.
Qualification of each surrogate response biomarker
(e.g. the proliferation marker FLT) will be necessary
for quantitative studies to demonstrate the clinical effi-
cacy of new agents. The availability of suitable radiotra-
cers to study apoptosis, and anti-cancer targets such as
the VEGF receptor, will permit increased apoptosis, or
changes in the expression level of molecular targets, to be
used as surrogate response biomarkers.
Assessing therapy response
Several different grading systems can be used to assess
the histological response of a tumour to treatment. The
Miller-Payne system is widely used; this compares tumour
cellularity before and after treatment[48]. Tumours are
graded on a 1 to 5 scale: 1, no response to treatment;
2,530% reduction in cellularity; 3, 3090% reduction in
cellularity; 4,490% and5100% reduction in cellularity;
and 5, complete response.
One of the greatest clinical needs in breast cancer is to
find an early and accurate way to determine which
patients are responding to therapy. This could signifi-
cantly improve clinical outcome by allowing non-respond-
ing patients to be prescribed a different anti-cancer
treatment at an early stage, when it still has the potential
to be effective. Several FDG studies have demonstrated
that decreases in the SUV of glucose metabolism[4244,49]
correspond with response to chemotherapy treatments.
In these studies it was possible to distinguish between
responders and non-responders when response was eval-
uated after either one (early evaluation) or two or more
cycles (midtherapy evaluation) of chemotherapy.
New radiotracers such as the proliferation marker
FLT[45,46,50] and ligands that bind to the oestrogen recep-
tor[33,34] have also been used as surrogate response bio-
markers to evaluate therapy response. These tracers
complement FDG by permitting the evaluation of
response to targeted therapies[33,34,50] as well as che-
motherapeutic ones. Radiotracers that can measure apop-
tosis/cell death, and other targeted agents, will also be
beneficial, by introducing new PET assays to identify
patients who are responding to therapy.
Dynamic contrast-enhanced MRI has also been used
extensively to assess early treatment response with vary-
ing success (reviewed in Ref.[51]) but is still not used in
routine practice. One of the main problems is the lack of
agreement on the method to acquire and analyse the data
so it is difficult to compare the results from one site with
another.
Identification of recurrence
There is some evidence that FDG-PET may be useful for
detecting recurrent breast cancer[52]; it is more sensitive
than MRI, but less specific. PET is particularly good at
detecting nodal and osseous recurrence[12], but is poor at
detecting very small tumours[53]. PET can help to identify
patients with single site metastatic disease who are more
likely to benefit from surgery[12]. Sodium fluoride is
being promoted as a better tool to detect bone metastases
than technetium labelled radioisotopes. New PET tracers
with increased specificity or sensitivity could be very
useful for detecting recurrent disease. Whole-body MRI
and diffusion-weighted image (DWI) have been explored
to a limited extent for assessing recurrent disease[54], but
are not used in routine practice.
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Conclusion
FDG is by far the most extensively used PET radiotracer
and has demonstrated clinical utility in various tumour
types for diagnosis, staging or detection of residual/recur-
rent cancer. There are, however, some roles that FDG
cannot perform because of low uptake into the tumour,
high background signal or merely because of the inherent
characteristics of the FDG radiotracer. The availability of
new radiotracers, or new applications of established PET
radiotracers, will increase the utility of PET by providing
data from additional tumour types and previously inac-
cessible information on the cell biology of tumours. In
breast cancer this should facilitate improved staging,
tumour subtyping, identification of disease recurrence,
development of new therapies and assessment of therapy
response, thus creating an opportunity to progress
towards a more personalised approach to cancer care
and help improve clinical outcomes.
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